California Public Employees Retirement System Lowers Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

California Public Employees Retirement System cut its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 3.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 204,132 shares of the biopharmaceutical company's stock after selling 7,649 shares during the period. California Public Employees Retirement System owned 0.16% of Alnylam Pharmaceuticals worth $48,034,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Regeneron Pharmaceuticals Inc. acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $1,045,822,000. Norges Bank acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $577,941,000. Raymond James Financial Inc. bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $65,295,000. Jennison Associates LLC bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $61,160,000. Finally, Proficio Capital Partners LLC raised its holdings in Alnylam Pharmaceuticals by 25,929.6% during the fourth quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company's stock worth $45,570,000 after buying an additional 192,916 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the sale, the executive vice president now owns 12,881 shares of the company's stock, valued at approximately $3,240,344.36. This represents a 10.06 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CMO Pushkal Garg sold 1,548 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total transaction of $389,585.16. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares of the company's stock, valued at approximately $3,017,271.63. The trade was a 11.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,234 shares of company stock worth $19,958,097 in the last quarter. 1.50% of the stock is owned by company insiders.

Remove Ads

Analyst Upgrades and Downgrades

ALNY has been the subject of several recent research reports. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, March 21st. Redburn Atlantic began coverage on Alnylam Pharmaceuticals in a report on Monday, March 31st. They set a "buy" rating and a $353.00 price objective for the company. HC Wainwright reissued a "buy" rating and issued a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday. Wells Fargo & Company lifted their target price on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a research report on Friday, March 21st. Finally, Needham & Company LLC reissued a "buy" rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have issued a buy rating to the company's stock. According to MarketBeat.com, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $316.25.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock traded down $26.42 during trading on Friday, reaching $235.74. 1,881,579 shares of the company's stock traded hands, compared to its average volume of 844,661. The firm's 50-day moving average is $259.03 and its 200 day moving average is $260.14. The company has a market capitalization of $30.67 billion, a P/E ratio of -108.64 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.